ONL Therapeutics, Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
ONL Therapeutics (ONL) is a clinical stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease, including retinal detachment, glaucoma, dry age-related macular degeneration (AMD), and inherited retinal degeneration (IRD). Our portfolio of products is based on break-through technology that inhibits Fas (CD95)-mediated signaling in the eye. Fas signaling is a common response to retinal disease and injury which leads to retinal cell death – the root cause of vision loss. By advancing this breakthrough technology, ONL is pioneering an entirely new approach to preserving vision.
Our lead product, the synthetic peptide ONL1204, is currently being tested in a First-in-Human (FIH) Phase 1 safety clinical trial in patients with retinal detachment (RD). Initial data indicated that ONL1204 is safe and well-tolerated, demonstrating target engagement through the modulation of inflammatory cytokines, and showing early hints of efficacy.
Company Type:
Company Website:
Company HQ State:
Michigan
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
ONL1204 (small peptide, intravitreal injection)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
ONL Therapeutics, Inc.